African-American women. Over the last three decades, ovarian cancer incidence has remained stable in high-risk countries, while an increasing trend has been reported in low-risk countries. 1, 4 Factors associated with an increased risk for invasive epithelial ovarian cancer include age, race, nulliparity, family history of ovarian cancer, and history of endometrial or breast cancer. 4 There is a weak association between ovarian cancer and age at natural menopause and among women with early onset disease. Factors associated with a reduced risk are history of one or more full-term pregnancies, use of oral contraceptives, history of breast feeding, tubal ligation, and hysterectomy. 5 Risk decreased with the number of pregnancies and sterilization. Use of oral contraceptives significantly reduced risk of ovarian cancer and reduced slightly with duration of use. [6] [7] [8] Characterization of adnexal masses to identify patients with malignant ovarian mass preoperatively for referral to a cancer center for treatment has been extensively studied. 9, 10 The accuracy of ultrasonography in differentiating between benign and malignant adnexal masses is proportional to the expertise of the operator. 11, 12 Findings suggestive of malignancy in an adnexal mass include a solid component, thick septations (greater than 2 to 3 mm), bilaterality, Doppler flow to the solid component of the mass, and presence of ascites. 13 CA-125 (MUC16) has provided a useful serum tumor marker for monitoring response to chemotherapy, detecting disease recurrence, distinguishing malignant from benign pelvic masses, and potentially improving clinical trial design. [14] [15] [16] The normal value for a CA-125 depend on the lab running the test. In general, a level above 35 U/ml are considered abnormal. 17 The aims of this study were to evaluate the risk of malignancy index (RMI) incorporating menopausal status, serum CA-125 levels, and ultrasound features for discriminating benign from malignant pelvic masses and to evaluate the performance of the three different risk of malignancy indices Dr. Cipto Mangunkusumo Hospital.
METHODS
This is a retrospective study conducted from January 2008-December 2012 in patients diagnosed with ovarian mass. Patients admitted for surgery due to ovarian masses were included to this study. RMI 3 score was calculated based on ultrasonography (U) examination in Dr. Cipto Mangunkusumo hospital, CA-125 (measured in U/ml) test and menopausal status (M). Patients without final pa-thological report and incomplete data were excluded from study. Data were analyzed using SPSS 20 to evaluate RMI result and final pathological report in benign and malignant case.
Ultrasonography is scored based on five attributes suggestive of malignancy. These attributes are the presence of solid parts, multilocular cyst, ascites, bilateral lesions, and intra-abdominal metastases. One point is given for one or no presence of the attributes, and three points for more than one attributes. Menopausal woman is given three points, and non-menopausal woman is given one point. CA-125 is scored equal to the blood level of CA-125 (U/ml). RMI score ≥ 200 is considered to be high is of malignancy, and RMI score <200 is considered to be low risk of malignancy. RMI score was evaluated based on final pathologic report as benign or malignant case. When ovarian mass was malignant, it was staged based on Federation of Gynecology and Obstetrics (FIGO) classification.
RESULT
From 882 patients identified with ovarian masses from cancer registry, only 99 patients aged 17-70 y.o were included in this study. Most of the patients were nullyparity (28.3%), non-menopausal women (60.6%), normal body mass index (40.4%), and with stage IIIC ovarian cancer (33.3%). There were no significant difference between benign and malignant case based on age (p = 0.82), parity (p = 0.09), menopausal status (p = 0.6), and CA-125 mean (p = 0.162). Body Mass Index (BMI) showed significant difference between benign and malignant case (p = 0.011). See Table 1 and 2. RMI and CA-125 showed good sensitivity (84.2 and 90.8), but Area Under Curve showed low performance (0.57 and 0.51). Our study showed that RMI, ultrasonography score, CA-125, and menopausal status has poor performance as triage tool.
RMI3=UxMxCA-125
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DISCUSSION
Many studies showed that Risk of malignancy index (RMI) is a valuable tool to differ benign from malignant ovarian mass. It has been used widely to help clinician in daily practice encountering adnexal masses. 9, 18 RMI is non-invasive and simple to apply in daily clinical practice. 19 RMI has been through 4 times modification since it was first introduced in 1990 by Jacob et al. 20 The last modification (RMI 4) was introduced in 2009 by Yamamoto et al, which is added tumor size in calculation. 21 In our study, RMI had good sensitivity (84.2) but poor specificity (30.4). RMI showed good performance as screening tool but poor performance as triage tool to differ benign from malignant ovarian mass. Moreover, Area Under Curve of RMI showed low significance level (0.57). Other study conducted by Ong C et al in Singapore showed similar result with our study. Ong C et al concluded that RMI 1, RMI 2, RMI 3, RMI 4 showed no statistical difference to differ benign from malignant cases in Southeast Asian population. 19 The components of RMI also showed no statistical difference between benign and malignant case. CA-125 showed the higher sensitivity (90.8) with the lowest specificity (13.0). This finding is consistent with other studies. Metaanalysis study showed that CA-125 has good sensitivity for detection malignant ovarian mass, but poor specificity. 22, 23 CA-125 level was influenced by several factors, including age, smoking status, ethnicity, and history of breast cancer. Meanwhile, history of previous gynecological operation and obesity lower the CA-125 level. 23 Evaluation of ovarian mass based on ultrasonography depends on examiner's experience. Experienced ultrasonography examiner can determine benign or malignant adnexal mass accurately. 24 Van Calster et al showed that 93% of tumor were correctly categorized as benign of malignant by pattern recognition. 25 Moreover, pattern recognition was superior than CA-125 to differ benign from malignant ovarian case. 25 There are several limitation in this study, such as small number of cases. Eventhough, many cases were identified, only few of them could be analyzed. The problems were medical record storage system. Many medical records were not found to be reviewed, and few of them with incomplete data. Others limiting factors in our study included its retrospecitve nature and limited time to do the research.
CONCLUSION
Our study showed that RMI was not accurate as triage tool for ovarian cancer in our hospital. Further investigation and more patients are needed to confirm this study.
